Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to determine whether reduction of serum calcium concentration by cinacalcet leads to reduction of mean blood pressure adjusted c-fPWV. The secondary objectives are to study the effects of calcium reduction on 1) carotid-radial PWV (c-rPWV), 2) common carotid artery (CCA) biomechanics, 3) pulse wave profile and cardiac function.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Laval University
• Collaborator: Amgen
• Treatments: Cinacalcet; Cinacalcet Hydrochloride

Criteria

Inclusion Criteria:

• chronic (> 3 months) hemodialysis population of > 18 years old

• PTH > 300 ng/L

• corrected Ca > 2.10 mmol/L

• stable hypertensive drugs (> 1 month)

• stable doses of phosphate binders and dialysis calcium concentration

• palpable femoral pulse

• systolic BP of 90-180 mmHg

• expected survival of > 6 months

Exclusion Criteria:

• hemodialysis > 3 years

• acute infection

• history of myocardial infarction or stroke within the past 3 months

• inability to consent

• intolerance to cinacalcet

• inadequate birth control